Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans
- PMID: 9733662
Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans
Abstract
In humans, a major metabolite of the atypical antipsychotic olanzapine in the plasma and in the urine was found to be an N-glucuronide. Unexpectedly, the glucuronic acid moiety was linked through a nitrogen of the benzodiazepine nucleus of olanzapine by way of a secondary amine linkage, rather than through a nitrogen on the piperazine substituent of the nucleus, to give a quaternary ammonium glucuronide. Derivatization with phenylisothiocyanate to yield a thiourea adduct indicated that conjugation occurred via a secondary amine. Subsequently, mass spectrometry and nuclear magnetic resonance studies with the isolated metabolite and later with the synthesized metabolite indicated that the glucuronide was linked at the 10- position of olanzapine. This phase 2 metabolite was only detected in the plasma and urine of human subjects and not in mice, rats, or monkeys; a trace of this metabolite was detected in dog urine. The N-10 glucuronide was resistant to enzymatic and base hydrolysis but was cleaved under acidic conditions. Formation of an N-glucuronide metabolite directly with the benzodiazepine nucleus has not previously been reported.
Similar articles
-
Disposition and biotransformation of the antipsychotic agent olanzapine in humans.Drug Metab Dispos. 1997 Jan;25(1):81-93. Drug Metab Dispos. 1997. PMID: 9010634
-
Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.Drug Metab Dispos. 1997 May;25(5):573-83. Drug Metab Dispos. 1997. PMID: 9152596
-
Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry.J Mass Spectrom. 1998 Dec;33(12):1237-45. doi: 10.1002/(SICI)1096-9888(199812)33:12<1237::AID-JMS742>3.0.CO;2-F. J Mass Spectrom. 1998. PMID: 9875525
-
Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience.Drug Metab Rev. 1999 Feb;31(1):15-28. doi: 10.1081/dmr-100101905. Drug Metab Rev. 1999. PMID: 10065363 Review. No abstract available.
-
Olanzapine. Pharmacokinetic and pharmacodynamic profile.Clin Pharmacokinet. 1999 Sep;37(3):177-93. doi: 10.2165/00003088-199937030-00001. Clin Pharmacokinet. 1999. PMID: 10511917 Review.
Cited by
-
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Pharmacogenet Genomics. 2011 Sep;21(9):539-51. doi: 10.1097/FPC.0b013e328348c76b. Pharmacogenet Genomics. 2011. PMID: 21750471 Free PMC article.
-
A 6-year retrospective study of olanzapine plasma concentration inpatients with schizophrenia CYP1A2 polymorphisms in real-life settings.Heliyon. 2024 Oct 18;10(20):e39367. doi: 10.1016/j.heliyon.2024.e39367. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39498058 Free PMC article.
-
Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases in liver microsomes from humans and animals.Acta Pharmacol Sin. 2010 Dec;31(12):1635-42. doi: 10.1038/aps.2010.172. Acta Pharmacol Sin. 2010. PMID: 21127497 Free PMC article.
-
Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.Antimicrob Agents Chemother. 2011 Apr;55(4):1504-9. doi: 10.1128/AAC.00883-10. Epub 2011 Jan 31. Antimicrob Agents Chemother. 2011. PMID: 21282425 Free PMC article. Clinical Trial.
-
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.Br J Clin Pharmacol. 2010 Dec;70(6):854-69. doi: 10.1111/j.1365-2125.2010.03791.x. Br J Clin Pharmacol. 2010. PMID: 21175441 Free PMC article.